Investigating Clostridium Difficile Infection in Infants

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the epidemiological characteristics and biomarkers associated with Clostridium difficile infection (CDI) in infants. By analyzing historical medical data and patient questionnaires, the study will identify prevalence, risk factors, and unique biomarkers linked to CDI in pediatric patients. The objectives include evaluating demographic and clinical characteristics, assessing high-risk factors, and establishing baseline biomarkers to enhance diagnosis and treatment strategies for affected infants.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Infants ( aged 0-2 years). Medical records and patient questionnaires available with confirmed Clostridium difficile infection (for case group) or without infection (for control group).

Exclusion Criteria:

* Infants beyond the age of 2 years at the time of diagnosis. Incomplete medical records or missing essential information related to infection status, feeding methods, or antibiotic exposure.Patients with other severe gastrointestinal conditions that may confound results.

Where it's running

• Hangzhou First People's Hospital
  Hangzhou, Zhejiang, China, China Recruiting

Study contacts

• Study coordinator: Li Qian Wang, Master of Medicine
• Email: wanglq921206@163.com
• Phone: 86+18768156110

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Orally ingested yeast designed to express a tetra-specific anti-toxin for Clostridioides difficile safety study

  This first-in-human trial tests a yeast-based medicine (FZ002) to see if it is safe and tolerable for adults with no active infection, using a placebo for comparison.

  Recruiting Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · Knoxville, Tennessee · NCT07649096

• Oral vancomycin to prevent C. difficile infection in critically ill adults

  This trial sees if taking oral vancomycin can prevent C. difficile infection in critically ill adults who are receiving systemic antibiotics.

  Recruiting Phase 2/3 Riverside University Health System Medical Center · Moreno Valley, California · NCT07221370

• Investigating factors related to Clostridioides difficile infection recurrence

  This study is trying to find out how certain body factors, like gut bacteria and genetics, affect the chances of Clostridioides difficile infection coming back in adults who have already been diagnosed with it.

  Recruiting at 12 sites Hospital Universitario de Valme · Alicante, Alicante and 14 other locations · NCT04801862

• Using alanyl-glutamine to treat C. difficile infections

  This study is testing if taking alanyl-glutamine can help people with C. difficile infections recover better and prevent the infection from coming back.

  Recruiting at 2 sites Phase 2 University of Virginia · Charlottesville, Virginia and 1 other locations · NCT04305769

• Using fecal microbiota transplantation to treat gut disorders

  This study is testing whether a treatment that involves using healthy stool to help restore gut bacteria can improve symptoms for people with gut disorders like Crohn's disease and irritable bowel syndrome.

  Recruiting Chinese University of Hong Kong · Hong Kong, Shatin · NCT04014413

• Fecal Transplant for Clostridioides difficile Infection

  This project tests fecal microbiota transplantation for adults with Clostridioides difficile infection to see if it helps treat the illness.

  Recruiting University of Aarhus · Aarhus N · NCT03712722

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.